MADRID, July 4 (Reuters) - The likely relocation of the
European Medicines Agency (EMA) from London threatens to disrupt
the approval of new drugs and is a medium and long-term worry
for top Spanish drugmaker Almirall, its chief executive
said on Monday.
Read more
No comments:
Post a Comment